November 12, 2026 09:00 AM PST
(PenniesToSave.com) – Some of the most widely used prescription drugs in the country are getting a new warning label. On Monday, Nov. 9, the U.S. Food and Drug Administration said it is requiring makers of GLP-1 drugs to add information about a rare eye condition that can lead to permanent vision loss [3]. The requirement covers household names such as Ozempic and Wegovy from Novo Nordisk and Mounjaro and Zepbound from Eli Lilly, part of a class of roughly a dozen injectable and pill-based drugs [1][3]. About 30 million people in the United States take these medications to treat diabetes and obesity and to lower cardiovascular risk, according to Ziyad Al-Aly, a clinical epidemiologist at Washington University in St. Louis [2].
The action is a disclosure, not a ban. The FDA is changing what the label says, not pulling the drugs from pharmacy shelves. The agency describes the added risk as small, the drugmakers dispute that their products cause the condition, and eye doctors are urging patients to stay calm and stay informed [4][5][6]. Each of those positions rests on the same set of numbers, and those numbers deserve a close look before anyone makes a decision about their own health.
Quick Links
- What Did the FDA Announce About GLP-1 Drugs?
- What Is NAION and How Does It Affect Vision?
- How Strong Is the Evidence Linking These Drugs to Vision Loss?
- How Are Drugmakers and Doctors Responding?
- How Does the U.S. Warning Compare With Europe’s?
- What Should Patients Weigh Before Changing Their Treatment?
What Did the FDA Announce About GLP-1 Drugs?
The FDA said it is requiring GLP-1 drugmakers to add information about the potential increased risk of non-arteritic anterior ischemic optic neuropathy, known as NAION, to the Warnings and Precautions section of their labeling [3]. Unlike earlier actions overseas that focused on a single ingredient, the U.S. requirement applies to every GLP-1 medication, and the agency said NAION cases have been reported for all GLP-1 products currently on the market [4].
The review behind the decision drew on several kinds of evidence. According to Reuters, the agency evaluated clinical trial data, animal data, and post-marketing data, including observational studies and case reports [3]. AP reported that the FDA also found reports of the problem in its electronic tracking system for drug injuries and side effects [1].
FDA scientists began examining the issue after a 2024 medical paper tied the condition to certain patients taking semaglutide, the active ingredient in Ozempic and Wegovy [1][5]. Even after that review, the agency said the underlying cause of the condition is not understood [1]. The announcement drew wide coverage, including a segment on NPR’s Here & Now Anytime in which STAT biotech reporter Elaine Chen walked through the findings and whether patients should be concerned [7].
The approach itself is worth noting. Rather than restricting access, regulators chose to put the information in front of patients and prescribers and let them weigh it. For a class of drugs this popular, a label change preserves personal choice while making sure that choice is an informed one.
A label change preserves personal choice while making sure that choice is an informed one.
PenniesToSave.com
What Is NAION and How Does It Affect Vision?
NAION is an injury to the optic nerve, the nerve that connects the eye to the brain [2]. It occurs when blood flow to the front part of the optic nerve drops, depriving the nerve of oxygen [4][6]. Doctors often describe it as a stroke of the eye [2].
The symptoms tend to arrive suddenly and without pain. Patients may notice blurred vision, blind spots, distorted colors, or partial loss of sight, usually in one eye [1][5][6]. Al-Aly wrote that many people first notice the change when they wake up, because the condition tends to strike at night when blood pressure naturally runs lower [2].
The stakes are high for anyone it affects. There is no known treatment to reverse vision loss caused by NAION, according to the American Academy of Ophthalmology [6]. Fox Business reported that about 43% of patients with significant vision impairment see some spontaneous improvement, though the outlet did not name the research behind that figure and noted that gaps in the visual field often persist [5].
Context helps keep the risk in proportion. The academy says NAION is the most common cause of acute optic nerve injury in people over 50 [6]. Diabetes, high blood pressure, and sleep apnea are known risk factors, and those same conditions are common among people prescribed GLP-1 drugs [5]. That overlap made it difficult for the FDA to determine whether the medications themselves were responsible for the cases it found, according to Fox Business [5]. In other words, NAION is a common cause of sudden vision loss in older adults, yet it remains a rare side effect of these medications [3][5]. Both statements are true at the same time, and keeping them separate is the key to reading this news clearly.
How Strong Is the Evidence Linking These Drugs to Vision Loss?
The FDA’s central analysis pooled 126 randomized clinical trials covering 134,253 patients, of whom 78,217 took a GLP-1 drug and 56,036 received a placebo or a different medication [2]. CNBC reported that the analysis found 6.4 cases of NAION per 100,000 patient-years among GLP-1 users, compared with 3.8 among those on other treatments or placebo [4]. That works out to a rate roughly 68% higher, though the FDA cautioned that the findings do not establish a causal link [5].
In absolute terms, the numbers are small. The FDA identified 15 probable NAION events in the trials, 10 among patients on GLP-1 drugs and five among those on placebo [4]. Ten cases among roughly 78,000 patients comes to about 0.01% [5].
Ten probable cases among roughly 78,000 patients on GLP-1 drugs comes to about 0.01%.
CNBC [4]; Fox Business [5]
The agency’s real-world data told a more mixed story. Compared with patients taking DPP-4 inhibitors, GLP-1 users showed a statistically significant increase in risk, but no significant increase appeared compared with patients taking SGLT-2 inhibitors such as Jardiance and Farxiga [4]. Al-Aly reported the DPP-4 comparison as 32 versus 26 cases per 100,000 over one year [2].
Outside studies have reported larger effects. A 2024 study of about 17,000 patients found those taking semaglutide were four times more likely to be diagnosed with NAION, though co-author Dr. Joseph Rizzo of Harvard Medical School described the findings as tentative and called for more research in a more diverse population [6]. A 2025 study of nearly 175,000 diabetic patients found the risk more than doubled after two years of GLP-1 treatment [3]. Al-Aly’s own study of nearly 600,000 U.S. veterans found about 390 cases per 100,000 among GLP-1 users, compared with 290 among those on other medications [2].
Al-Aly, whose research helped identify the link, wrote that the risk is likely real [2]. The FDA, the academy, and Novo Nordisk all say a causal relationship has not been established [4][5][6]. The estimates vary because the studies looked at different patients over different periods, so weighing them side by side tells a more honest story than any single figure.
How Are Drugmakers and Doctors Responding?
The companies behind the drugs responded quickly. Novo Nordisk, which makes Ozempic and Wegovy, said it “continues to believe the data do not establish a cause-and-effect relationship” [4]. The company also said patient safety is a top priority and that it continues to monitor the safety of its medicines [6].
Eli Lilly, maker of Mounjaro, Zepbound, and Foundayo, said it is carefully evaluating the update and will respond to the FDA promptly, adding that patient safety is its top priority [4]. A Lilly spokesperson also noted that the FDA’s communication applies to all GLP-1 medicines and does not reference findings specific to Lilly’s drugs [3].
Wall Street weighed in as well. Citi analyst Geoff Meacham said the action may temporarily increase patient and investor concern, but argued that the rarity of NAION and the drugs’ weight, blood sugar, heart, kidney, and sleep apnea benefits should preserve a favorable balance of benefit and risk and limit changes in prescribing [3][4]. For anyone investing in individual stocks, the episode shows how a single regulatory announcement can shift sentiment around even the largest drugmakers.
The American Academy of Ophthalmology struck a measured tone. In a statement to the BBC, the group said any added risk appears small and that it has not been established that these medications cause NAION, while emphasizing their benefits for people with diabetes, obesity, and heart disease [6].
Every party here brings a perspective worth hearing, and the drugmakers in particular have a financial stake in how their products are perceived. Weighing each statement with that in mind is simple common sense, and it applies just as much to alarming headlines as to reassuring press releases.
How Does the U.S. Warning Compare With Europe’s?
The United States is not the first to act. European regulators flagged a NAION risk associated with semaglutide in June 2025 [4]. The European Medicines Agency’s safety committee concluded that NAION is a very rare side effect that may affect up to 1 in 10,000 people taking semaglutide for at least one year, and Reuters reported that this was the first time a regulator had confirmed the side effect [3][4].
Accounts differ on how firm that step was. CNBC reported that the committee recommended updating the drug’s product information [4], while Al-Aly wrote that European regulators mandated the package insert update [2]. The U.K.’s medicines regulator followed with a similar warning in February, according to CNBC [4].
Some patients in Europe have also received compensation. Reuters reported that four patients in Denmark who experienced vision loss after using Novo’s GLP-1 drugs were granted compensation, according to the Danish Patient Compensation [3].
The American action is broader in scope. The European and British warnings focused specifically on semaglutide, while the FDA’s requirement covers every GLP-1 medication [4]. That breadth reflects the agency’s finding that cases have appeared across the entire class [4]. Some will see the U.S. as slow to follow Europe’s lead, while others will see value in a more comprehensive review before acting. Either way, American patients now have the same kind of information European patients received more than a year ago.
What Should Patients Weigh Before Changing Their Treatment?
The new warning joins a list of risks already printed on these labels. Many GLP-1 drugs carry the FDA’s strongest safety warning, a boxed warning, over a potential risk of thyroid tumors seen in rodent studies, though it remains unknown whether the drugs cause such tumors in humans [4]. Semaglutide and tirzepatide also carry warnings about diabetic retinopathy, another eye condition. In a two-year trial of type 2 diabetes patients at high cardiovascular risk, retinopathy complications occurred in 3% of those on Ozempic, compared with 1.8% on placebo [4]. The labels already warn about pancreatitis and gallbladder disease as well [6].
None of that means the drugs are the wrong choice. It means they are serious medications whose benefits and risks deserve an honest conversation, and the American Academy of Ophthalmology offered direct advice on how to start one [6].
“Don’t stop your medication without talking to your doctor.” [6]
American Academy of Ophthalmology, in a statement to the BBC
The academy also urged anyone who notices sudden, painless vision loss in one eye to see an ophthalmologist promptly [6]. The FDA advised patients experiencing blurred vision, blind spots, or other visual changes to contact a health care professional immediately [1].
Some patients face higher stakes than others. Al-Aly wrote that people who have previously had NAION, or who have risk factors such as smoking, diabetes, high blood pressure, sleep apnea, anemia, or kidney disease, should have a careful discussion with their doctor weighing risks and benefits [2]. He also wrote that for people using the drugs for an FDA-approved condition on a doctor’s advice, the risk should not deter them [2].
That distinction matters. The decision belongs to each patient and their doctor, and anyone taking these drugs outside an approved use has extra reason to ask whether the benefit justifies the risk.
Final Thoughts
The FDA’s new warning adds information without taking anything away. GLP-1 drugs remain available, and patients and doctors now have a clearer picture of a rare but serious risk. The agency’s own trial data point to a small absolute increase, about 10 probable cases among roughly 78,000 patients on the drugs, while outside studies suggest the effect could be larger in certain groups [3][4][5][6]. Causation has not been established, and the research is still developing.
GLP-1 drugs have drawn enormous enthusiasm, and the benefits are real, from weight and blood sugar control to heart, kidney, and sleep apnea improvements, as Citi analysts noted [4]. Yet no medication is free of tradeoffs, and enthusiasm should not crowd out caution any more than fear should crowd out facts. The European experience shows regulators on both sides of the Atlantic reached similar conclusions, which lends the warning weight without making it a reason for panic [2][4].
The most sensible path is a familiar one. Know the symptoms, take any sudden change in vision seriously, and make treatment decisions with a trusted doctor rather than on the strength of a headline.
Works Cited
[1] Perrone, Matthew. “FDA Adds Rare Vision-Loss Warning to Popular GLP-1 Drugs.” AP News, Associated Press, 10 Nov. 2026, apnews.com/article/glp1-drugs-vision-loss-warning-d85a58ea769bc12cc1989e914a51f248.
[2] Al-Aly, Ziyad. “GLP-1 Drugs Carry Risk of Rare but Serious Eye Condition: A Physician Studying These Medicines Explains the Potential Side Effect.” The Conversation, 10 Nov. 2026, theconversation.com/glp-1-drugs-carry-risk-of-rare-but-serious-eye-condition-a-physician-studying-these-medicines-explains-the-potential-side-effect-296237.
[3] Reuters. “US FDA Orders New Eye Risk Warnings for Ozempic, Zepbound.” CNN, 9 Nov. 2026, www.cnn.com/2026/11/09/health/glp1-vision-loss-fda-warning.
[4] Ohlen, Elsa. “FDA Warns of Vision Loss Risk Linked to Popular GLP-1 Drugs like Wegovy, Zepbound.” CNBC, 11 Nov. 2026, www.cnbc.com/2026/11/10/fda-warning-vision-loss-glp1-wegovy-zepbound.html.
[5] Cirrone, James. “FDA Orders New Warning Labels on Ozempic, Wegovy over Rare Risk of Permanent Vision Loss.” Fox Business, 10 Nov. 2026, www.foxbusiness.com/healthcare/fda-orders-new-warning-labels-ozempic-wegovy-over-rare-risk-permanent-vision-loss.
[6] Halpert, Madeline. “Makers of GLP-1 Drugs Ordered to Add Warnings about Rare Eye Condition That Can Lead to Blindness.” BBC News, 10 Nov. 2026, www.bbc.com/news/articles/crwydyde0lp3o.
[7] Young, Robin, et al. “FDA Warns GLP-1s Could Increase Risk of Vision Loss.” Here & Now Anytime, NPR, 10 Nov. 2026, www.npr.org/2026/11/10/nx-s1-6035824/fda-warns-glp-1s-could-increase-risk-of-vision-loss.